following a full submission:
fremanezumab (Ajovy®) is accepted for restricted use within NHSScotland.
Indication under review: For prophylaxis of migraine in adults who have at least four migraine days per month.
SMC restriction: for the treatment of patients with chronic and episodic migraine who have had prior failure on three or more migraine preventive treatments.
Three phase III studies demonstrated superiority of fremanezumab over placebo in reducing the number of monthly migraine days in patients with chronic and episodic migraine.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
- Medicine name:
- fremanezumab (Ajovy)
- SMC ID:
For the prophylaxis of migraine in adults who have at least four migraine days per month.
- Pharmaceutical company
- Teva UK Limited
- BNF chapter
- Central nervous system
- Submission type
- Date advice published
- 13 January 2020